(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 28.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Omniab's revenue in 2025 is $26,391,000.On average, 5 Wall Street analysts forecast OABI's revenue for 2025 to be $2,951,757,254, with the lowest OABI revenue forecast at $2,772,463,161, and the highest OABI revenue forecast at $3,103,448,851. On average, 5 Wall Street analysts forecast OABI's revenue for 2026 to be $4,017,995,289, with the lowest OABI revenue forecast at $3,151,081,478, and the highest OABI revenue forecast at $5,592,558,948.
In 2027, OABI is forecast to generate $7,514,962,920 in revenue, with the lowest revenue forecast at $4,360,217,394 and the highest revenue forecast at $9,635,225,495.